Junghyun Jo

Prof. Dr. Junghyun Jo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Annals of Neurology
Verified
Journal Article
Open access
JJJunghyun Jo
Junghyun Jo
LYLin Yang
Lin Yang
HTHoang‐Dai Tran
Hoang‐Dai Tran
WYWeonjin Yu
Weonjin Yu
ASAlfred Xuyang Sun
Alfred Xuyang Sun
HJHyunsoo Shawn Je
Hyunsoo Shawn Je
Objective: We utilized human midbrain‐like organoids (hMLOs) generated from human pluripotent stem cells carrying glucocerebrosidase gene (GBA1) and α‐synuclein (α‐syn; SNCA) perturbations to investigate genotype‐to‐phenotype relationships in Parkinson disease, with the particular aim of recapitulating α‐syn– and Lewy body–related pathologies and the process of neurodegeneration in the hMLO model.Methods: We generated and characterized hMLOs from GBA1−/− and SNCA overexpressing isogenic embryonic stem cells and also generated Lewy body–like inclusions in GBA1/SNCA dual perturbation hMLOs and conduritol‐b‐epoxide–treated SNCA triplication hMLOs.Results: We identified for the first time that the loss of glucocerebrosidase, coupled with wild‐type α‐syn overexpression, results in a substantial accumulation of detergent‐resistant, β‐sheet–rich α‐syn aggregates and Lewy body–like inclusions in hMLOs. These Lewy body–like inclusions exhibit a spherically symmetric morphology with an eosinophilic core, containing α‐syn with ubiquitin, and can also be formed in Parkinson disease patient–derived hMLOs. We also demonstrate that impaired glucocerebrosidase function promotes the formation of Lewy body–like inclusions in hMLOs derived from patients carrying the SNCA triplication.Interpretation: Taken together, the data indicate that our hMLOs harboring 2 major risk factors (glucocerebrosidase deficiency and wild‐type α‐syn overproduction) of Parkinson disease provide a tractable model to further elucidate the underlying mechanisms for progressive Lewy body formation. ANN NEUROL 2021;90:490–505

Verified
Journal Article
Open access
PDF file
MINKYOUNG SHINMINKYOUNG SHIN
MINKYOUNG SHIN
JBJin Seok Bang
Jin Seok Bang
JLJeoung Eun Lee
Jeoung Eun Lee
HTHoang-Dai Tran
Hoang-Dai Tran
GPGenehong Park
Genehong Park
JJJunghyun Jo
Junghyun Jo
In vitro organoids derived from human pluripotent stem cells (hPSCs) have been developed as essential tools to study the underlying mechanisms of human development and diseases owing to their structural and physiological similarity to corresponding organs. Despite recent advances, there are a few methodologies for three-dimensional (3D) skeletal muscle differentiation, which focus on the terminal differentiation into myofibers and investigate the potential of modeling neuromuscular disorders and muscular dystrophies. However, these methodologies cannot recapitulate the developmental processes and lack regenerative capacity. In this study, we developed a new method to differentiate hPSCs into a 3D human skeletal muscle organoid (hSkMO). This organoid model could recapitulate the myogenesis process and possesses regenerative capacities of sustainable satellite cells (SCs), which are adult muscle stem/progenitor cells capable of self-renewal and myogenic differentiation. Our 3D model demonstrated myogenesis through the sequential occurrence of multiple myogenic cell types from SCs to myocytes. Notably, we detected quiescent, non-dividing SCs throughout the hSkMO differentiation in long-term culture. They were activated and differentiated to reconstitute muscle tissue upon damage. Thus, hSkMOs can recapitulate human skeletal muscle development and regeneration and may provide a new model for studying human skeletal muscles and related diseases.

13 November 2023 in Frontiers in Neuroscience
Verified
Journal Article
Open access
CDCharlotte R. Denman
Charlotte R. Denman
SPSang Myun Park
Sang Myun Park
JJJunghyun Jo
Junghyun Jo
Gut dysbiosis and psychiatric symptoms are common early manifestations of Alzheimer’s disease (AD) and Parkinson’s disease (PD). These diseases, characterised by progressive neuron loss and pathological protein accumulation, impose debilitating effects on patients. Recently, these pathological proteins have been linked with gut dysbiosis and psychiatric disorders. The gut-brain axis links the enteric and central nervous systems, acting as a bidirectional communication pathway to influence brain function and behavior. The relationship triad between gut dysbiosis, psychiatric disorders, and neurodegeneration has been investigated in pairs; however, evidence suggests that they are all interrelated and a deeper understanding is required to unravel the nuances of neurodegenerative diseases. Therefore, this review aims to summarise the current literature on the roles of gut dysbiosis and psychiatric disorders in pathological protein-related neurodegenerative diseases. We discussed how changes in the gut environment can influence the development of psychiatric symptoms and the progression of neurodegeneration and how these features overlap in AD and PD. Moreover, research on the interplay between gut dysbiosis, psychiatric disorders, and neurodegeneration remains in its early phase. In this review, we highlighted potential therapeutic approaches aimed at mitigating gastrointestinal problems and psychiatric disorders to alter the rate of neurodegeneration. Further research to assess the molecular mechanisms underlying AD and PD pathogenesis remains crucial for developing more effective treatments and achieving earlier diagnoses. Moreover, exploring non-invasive, early preventive measures and interventions is a relatively unexplored but important avenue of research in neurodegenerative diseases.

13 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
ATAhmed Tanvir
Ahmed Tanvir
JJJunghyun Jo
Junghyun Jo
SPSang Myun Park
Sang Myun Park
Glucose metabolism is essential for the maintenance and function of the central nervous system. Although the brain constitutes only 2% of the body weight, it consumes approximately 20% of the body’s total energy, predominantly derived from glucose. This high energy demand of the brain underscores its reliance on glucose to fuel various functions, including neuronal activity, synaptic transmission, and the maintenance of ion gradients necessary for nerve impulse transmission. Increasing evidence shows that many neurodegenerative diseases, including Parkinson’s disease (PD), are associated with abnormalities in glucose metabolism. PD is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accompanied by the accumulation of α-synuclein protein aggregates. These pathological features are exacerbated by mitochondrial dysfunction, oxidative stress, and neuroinflammation, all of which are influenced by glucose metabolism disruptions. Emerging evidence suggests that targeting glucose metabolism could offer therapeutic benefits for PD. Several antidiabetic drugs have shown promise in animal models and clinical trials for mitigating the symptoms and progression of PD. This review explores the current understanding of the association between PD and glucose metabolism, emphasizing the potential of antidiabetic medications as a novel therapeutic approach. By improving glucose uptake and utilization, enhancing mitochondrial function, and reducing neuroinflammation, these drugs could address key pathophysiological mechanisms in PD, offering hope for more effective management of this debilitating disease.


14 August 2025 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
SPSeongjun Park
Seongjun Park
MSMin‐Kyoung Shin
Min‐Kyoung Shin
DJDong Seok Jeong
Dong Seok Jeong
XYXin Yi Yeo
Xin Yi Yeo
YKYeo Jin Kim
Yeo Jin Kim
JJJunghyun Jo
Junghyun Jo
Background: Sarcopenia is defined by the age‐related loss of muscle mass and function, with an impaired regenerative capacity of satellite cells (SCs). Despite their recognized importance in muscle regeneration, human model‐based studies on SCs in sarcopenia are still lacking, limiting our understanding of their role in age‐related muscle loss. Here, we aimed to develop a sarcopenia model using human pluripotent stem cells (hPSCs)‐derived skeletal muscle organoids (hSkMOs) and prevent the sarcopenia progression by testosterone treatment.Methods: The 3D hSkMOs were generated from hPSC and exhibited structurally and functionally mature muscle fibres and spinal‐derived neurons including motor neurons and interneurons. The proportion of muscle and the diameter of muscle fibres were assessed. To investigate the acute pro‐inflammatory response and intrinsic regenerative capacity of hSkMOs, we induced sarcopenia‐like conditions by TNF‐α treatment for 2 days and analysed. To model aging‐induced sarcopenia and investigate the preventive effect of testosterone, chronic TNF‐α treatment was applied, followed by testosterone administration. Histological, biochemical, molecular and electrophysiological analyses were conducted in various experiments.Result: We employed a stepwise differentiation protocol from 2D paraxial mesodermal induction to 3D myogenic specification, concluding with a maturation culture system. We observed that the majority of cells were T/BRA‐ and TBX6‐positive (+) paraxial mesodermal progenitors (T/BRA+, 82.04%; TBX6+, 78.18%), whereas the neuromesodermal progenitors demonstrated a relatively low proportion (T/BRA+/SOX2+, 15.91%; TBX6+/SOX2+, 11.45%). Single‐nucleus RNA‐sequencing and extensive immunohistochemistry confirmed the presence of the myogenic lineage cell types (myogenic progenitors/SCs, myocytes, muscle fibres) and the neural lineage cell types (spinal‐derived interneurons, motor neurons, glial cells, Schwann cells). Additionally, the growth of MyHC+ muscle fibres reached twice the thickness on Day 100 compared to that on Day 50 (p < 0.0001). We subjected them to TNF‐α treatment and analysed. Western blot analysis confirmed that TNF‐α/NF‐κB pathway associated factors such as NF‐κB p65, IκB‐α and AKT were highly phosphorylated (p < 0.05, p < 0.001). The administration of testosterone increased the proportion of activated SCs (PAX7+/MYOD+, 7.97%; PAX7+/Ki67+, 7.03%) compared to the TNF‐α group (PAX7+/MYOD+, 2.29%; PAX7+/Ki67+, 2.07%, p < 0.001). The administration of testosterone increased the Cross‐Sectional‐Area (987.1 μm2) compared to the TNF‐α group (644.7 μm2, p < 0.01).Conclusions: We successfully developed a hSkMOs to demonstrate the structural maturity of the skeletal muscle and its functional interaction with spinal‐derived interneurons and motor neurons. Furthermore, we demonstrated that our hSkMOs are useful for modelling aging‐induced sarcopenia and providing a valuable platform for testing therapeutic interventions.